Halozyme sees FY26 EPS $7.75-$8.25, consensus $8.21

Sees FY26 revenue $1.71B-$1.81B, consensus $1.69B. Sees FY26 adjusted EBITDA $1.13B-$1.17B. Sees FY26 royalty revenue $1.13B-$1.17B. Torley added, “In the near-term, our strong 2026 total revenue expectations of 23% to 30% year-over-year growth underscore the strength of our royalty revenue, which is projected to exceed $1 billion in 2026, growing at 30% to 35% versus prior year. This is one year earlier than previously projected. By the end of 2026, we project we will have 15 partner programs in development and have signed three or more new drug delivery licensing agreements, expanding the reach and growing our opportunity through our diversified drug delivery portfolio. Taken together, these drivers reinforce our confidence in delivering durable revenue growth well into the 2040s and support our conviction in Halozyme’s (HALO) long-term growth profile which will deliver sustained value for shareholders.”